We are live on ! Find out more
ZVRA icon

Zevra Therapeutics
ZVRA

40 hedge funds and large institutions have $24.8M invested in Zevra Therapeutics in 2016 Q2 according to their latest regulatory filings, with 5 funds opening new positions, 18 increasing their positions, 9 reducing their positions, and 23 closing their positions.

New
Increased
Maintained
Reduced
Closed

100% more repeat investments, than reductions

Existing positions increased: 18 | Existing positions reduced: 9

31% less funds holding

Funds holding: 58 → 40 (-18)

50% less funds holding in top 10

Funds holding in top 10: 2 → 1 (-1)

77% less capital invested

Capital invested by funds: $106M → $24.8M (-$81.4M)

78% less first-time investments, than exits

New positions opened: 5 | Existing positions closed: 23

Holders
40
Holders Change
-18
Holders Change %
-31.03%
% of All Funds
1.07%
Holding in Top 10
1
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-50%
% of All Funds
0.03%
New
5
Increased
18
Reduced
9
Closed
23
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

1
Alyeska Investment Group
Alyeska Investment Group
Illinois
+$4.09M
2
SIM
Spark Investment Management
New York
+$959K
3
Point72 Asset Management
Point72 Asset Management
Connecticut
+$669K
4
DA
DSC Advisors
Illinois
+$513K
5
Millennium Management
Millennium Management
New York
+$377K

Top Sellers

1
Schroder Investment Management Group
Schroder Investment Management Group
United Kingdom
-$5.14M
2
BC
Broadfin Capital
New York
-$4.35M
3
SFM
Sphera Funds Management
Israel
-$2.67M
4
ECM
Endurant Capital Management
California
-$2.46M
5
AWA
Arete Wealth Advisors
Illinois
-$2.23M
Name Holding Trade Value Shares
Change 		Change in
Stake
DM
1
Deerfield Management
New York
$5.65M – – –
DA
2
DSC Advisors
Illinois
$3.75M +$513K +3,121 +6%
AWA
3
Arete Wealth Advisors
Illinois
$3.29M -$2.23M -13,538 -21%
Alyeska Investment Group
4
Alyeska Investment Group
Illinois
$3.23M +$4.09M +24,861 +96%
Point72 Asset Management
5
Point72 Asset Management
Connecticut
$1.52M +$669K +4,064 +20%
Vanguard Group
6
Vanguard Group
Pennsylvania
$1.27M +$107K +649 +3%
KCM
7
Kingdon Capital Management
New York
$1.03M +$224K +1,359 +9%
BFA
8
BlackRock Fund Advisors
California
$872K +$179K +1,087 +9%
Federated Hermes
9
Federated Hermes
Pennsylvania
$796K – – –
CWG
10
C WorldWide Group
Denmark
$657K – – –
DCM
11
Driehaus Capital Management
Illinois
$583K -$1.01M -6,143 -40%
SIM
12
Spark Investment Management
New York
$561K +$959K +5,830 +195%
Millennium Management
13
Millennium Management
New York
$239K +$377K +2,294 +158%
MC
14
Menta Capital
California
$187K +$366K +2,227 +312%
Geode Capital Management
15
Geode Capital Management
Massachusetts
$170K +$86.7K +527 +24%
BIT
16
BlackRock Institutional Trust
California
$135K -$16.9K -103 -5%
WHI
17
William Harris Investors
Illinois
$123K +$153K +932 +93%
PL
18
Parkwood LLC
Ohio
$107K +$276K +1,676 New
ISB
19
Iowa State Bank
Iowa
$80K +$11.8K +72 +6%
Northern Trust
20
Northern Trust
Illinois
$76K +$987 +6 +0.5%
EAM
21
Evanson Asset Management
California
$68K – – –
Goldman Sachs
22
Goldman Sachs
New York
$63K -$720K -4,377 -82%
VKH
23
Virtu KCG Holdings
New York
$61K +$159K +966 New
TC
24
TFS Capital
Pennsylvania
$53K -$200K -1,217 -59%
WS
25
Wedbush Securities
California
$46K +$118K +719 New
1
2 3

ZVRA Hedge Fund Activity: Q2 2016 in Review

40 of the 3,748 institutional investors tracked by Wall St. Rank reported a position in Zevra Therapeutics (ZVRA) for Q2 2016, worth a combined $24.8M — down 77% from $106M a quarter earlier.

Sellers outnumbered buyers: 23 funds closed out of ZVRA and 5 opened new positions — a net loss of 18 holders — while 9 trimmed existing stakes and 18 added.

The largest buyer was Alyeska Investment Group, adding an estimated $4.09M. The largest seller was Schroder Investment Management Group, exiting entirely with an estimated $5.14M sold.

  • 40 institutional investors held Zevra Therapeutics (ZVRA) as of Q2 2016, down from 58 in Q1 2016.
  • Funds reported $24.8M of Zevra Therapeutics stock for Q2 2016, down 77% quarter-over-quarter.
  • 5 funds opened new Zevra Therapeutics positions in Q2 2016 and 23 closed out, a net change of -18 holders.
  • The largest Zevra Therapeutics buyer in Q2 2016 was Alyeska Investment Group, an estimated $4.09M added.
  • The largest Zevra Therapeutics seller in Q2 2016 was Schroder Investment Management Group, an estimated $5.14M sold.

Based on aggregated 13F filings for Q2 2016.